IN2014DN09013A - - Google Patents
Info
- Publication number
- IN2014DN09013A IN2014DN09013A IN9013DEN2014A IN2014DN09013A IN 2014DN09013 A IN2014DN09013 A IN 2014DN09013A IN 9013DEN2014 A IN9013DEN2014 A IN 9013DEN2014A IN 2014DN09013 A IN2014DN09013 A IN 2014DN09013A
- Authority
- IN
- India
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261618215P | 2012-03-30 | 2012-03-30 | |
PCT/US2013/034214 WO2013148912A1 (fr) | 2012-03-30 | 2013-03-28 | Composés pour utilisation dans le traitement de neuroblastome, sarcome d'ewing ou un rhabdomyosarcome |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN09013A true IN2014DN09013A (fr) | 2015-05-22 |
Family
ID=48142079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN9013DEN2014 IN2014DN09013A (fr) | 2012-03-30 | 2014-10-28 |
Country Status (11)
Country | Link |
---|---|
US (2) | US20150051252A1 (fr) |
EP (1) | EP2830619A1 (fr) |
JP (1) | JP2015512416A (fr) |
KR (1) | KR20150002623A (fr) |
CN (1) | CN104244949A (fr) |
AU (1) | AU2013239624A1 (fr) |
CA (1) | CA2865993A1 (fr) |
IN (1) | IN2014DN09013A (fr) |
MX (1) | MX2014011843A (fr) |
RU (1) | RU2014143232A (fr) |
WO (1) | WO2013148912A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015078931A1 (fr) * | 2013-11-27 | 2015-06-04 | Oncoethix Sa | Méthode de traitement de neuroblastomes à l'aide de composés thiénotriazolodiazépine |
US10874631B2 (en) | 2016-12-21 | 2020-12-29 | The Board Of Regents Of The University Of Texas System | Altertoxin II as a selective inhibitor of Ewing family of tumor cells |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR044519A1 (es) * | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
KR20100093129A (ko) * | 2007-12-20 | 2010-08-24 | 노파르티스 아게 | Pi 3 키나제 억제제로서 사용되는 티아졸 유도체 |
UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
JP5819831B2 (ja) * | 2009-08-17 | 2015-11-24 | インテリカイン, エルエルシー | 複素環式化合物およびそれらの使用 |
WO2012175522A1 (fr) * | 2011-06-21 | 2012-12-27 | Novartis Ag | Polymorphes du 2-amide-1-({4-méthyl-5-[2-(2,2,2-trifluoro-1,1-diméthyl- éthyl)pyridin-4-yl]-thiazol-2-yl}-amide d'acide (s)-pyrrolidine-1,2-dicarboxylique |
MX359406B (es) * | 2011-07-01 | 2018-09-27 | Novartis Ag | Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3kpara usarse en el tratamiento de cáncer. |
US20140235630A1 (en) * | 2011-09-30 | 2014-08-21 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for the treatment of proliferative diseases |
US8980259B2 (en) * | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
-
2013
- 2013-03-28 KR KR1020147026928A patent/KR20150002623A/ko not_active Application Discontinuation
- 2013-03-28 CN CN201380012051.XA patent/CN104244949A/zh active Pending
- 2013-03-28 AU AU2013239624A patent/AU2013239624A1/en not_active Abandoned
- 2013-03-28 MX MX2014011843A patent/MX2014011843A/es unknown
- 2013-03-28 RU RU2014143232A patent/RU2014143232A/ru unknown
- 2013-03-28 EP EP13717371.2A patent/EP2830619A1/fr not_active Withdrawn
- 2013-03-28 WO PCT/US2013/034214 patent/WO2013148912A1/fr active Application Filing
- 2013-03-28 CA CA2865993A patent/CA2865993A1/fr not_active Abandoned
- 2013-03-28 JP JP2015503554A patent/JP2015512416A/ja active Pending
- 2013-03-28 US US14/387,636 patent/US20150051252A1/en not_active Abandoned
-
2014
- 2014-10-28 IN IN9013DEN2014 patent/IN2014DN09013A/en unknown
-
2016
- 2016-02-08 US US15/018,287 patent/US20160151344A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2830619A1 (fr) | 2015-02-04 |
CA2865993A1 (fr) | 2013-10-03 |
US20150051252A1 (en) | 2015-02-19 |
RU2014143232A (ru) | 2016-05-27 |
KR20150002623A (ko) | 2015-01-07 |
US20160151344A1 (en) | 2016-06-02 |
JP2015512416A (ja) | 2015-04-27 |
WO2013148912A1 (fr) | 2013-10-03 |
CN104244949A (zh) | 2014-12-24 |
AU2013239624A1 (en) | 2014-10-02 |
MX2014011843A (es) | 2014-12-10 |